207 related articles for article (PubMed ID: 32392373)
1. Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Self-Controlled Case Series Study.
Nam YH; Han X; Brensinger CM; Bilker WB; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2020 Nov; 108(5):1010-1017. PubMed ID: 32392373
[TBL] [Abstract][Full Text] [Related]
2. Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin.
Nam YH; Brensinger CM; Bilker WB; Leonard CE; Han X; Hennessy S
Clin Pharmacol Ther; 2019 Jan; 105(1):210-218. PubMed ID: 29885251
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Hee Nam Y; Brensinger CM; Bilker WB; Flory JH; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2022 Jan; 111(1):218-226. PubMed ID: 34312836
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.
Leonard CE; Brensinger CM; Bilker WB; Kimmel SE; Han X; Nam YH; Gagne JJ; Mangaali MJ; Hennessy S
Int J Cardiol; 2017 Feb; 228():761-770. PubMed ID: 27888753
[TBL] [Abstract][Full Text] [Related]
5. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
Romley JA; Gong C; Jena AB; Goldman DP; Williams B; Peters A
BMJ; 2015 Dec; 351():h6223. PubMed ID: 26643108
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
8. Warfarin with sulfonylureas and hypoglycemic events: consider dose, length of treatment, and all sulfonylureas.
Bosco-Lévy P; Salvo F
BMJ; 2016 Aug; 354():i4328. PubMed ID: 27495245
[No Abstract] [Full Text] [Related]
9. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
10. Individual sulfonylureas and serious hypoglycemia in older people.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
J Am Geriatr Soc; 1996 Jul; 44(7):751-5. PubMed ID: 8675920
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
12. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.
Carnahan RM; Gagne JJ; Hampp C; Leonard CE; Toh S; Fuller CC; Hennessy S; Hou L; Cocoros NM; Panucci G; Woodworth T; Cosgrove A; Iyer A; Chrischilles EA
Pharmaceut Med; 2019 Feb; 33(1):29-43. PubMed ID: 31933271
[TBL] [Abstract][Full Text] [Related]
15. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials.
Zhang F; Xiang H; Fan Y; Ganchuluun TA; Kong W; Ouyang Q; Sun J; Cao B; Jiang H; Nie S
Endocrine; 2013 Dec; 44(3):648-58. PubMed ID: 23657947
[TBL] [Abstract][Full Text] [Related]
16. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
17. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
18. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
20. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients.
Hauta-Aho M; Tirkkonen T; Vahlberg T; Laine K
Ann Med; 2009; 41(8):619-28. PubMed ID: 19711211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
